Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesArtiva Biotherapeutics, Inc. Common Stock

Artiva Biotherapeutics, Inc. Common Stock

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
4.22 USD 0.07 ( 1.69%)
Last update at 2026-11-09T21:05:00Z
VOLUME
933699
Market Cap
285.89M

Momentum Score

…

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
4.14
Low
4.25
High
52 Week Price Range
9.68
Low
17.31
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Artiva Biotherapeutics is a clinical-stage biotechnology company developing allogeneic natural killer (NK) and CAR-NK cell therapies for hematologic malignancies and selected solid tumors. Long-term growth drivers include clinical trial outcomes, scalable manufacturing to enable off-the-shelf products, and collaborations or regulatory approvals that may broaden indications and support commercialization.

Principal investment risks are high clinical and regulatory uncertainty, substantial financing and manufacturing scale-up requirements, and intense competition within the cell therapy and immuno-oncology sectors.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
4.15
Dividend Yield
-
Revenue TTM
2.60M
Revenue Per Share
0.48
Gross Profit TTM
0.00M
Debt / Equity
-0.10
ROE
-44.21%
Net Debt
-36.59M
ROCE
-33.02%
Diluted EPS TTM
-2.48

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -27.62M -58.34M -71.83M -17.99M
Net income -27.70M -58.39M -71.83M -17.99M
Selling general administrative 13.91M 20.78M 12.86M 4.43M
Gross profit 33.49M 4.93M 2.00M -
Reconciled depreciation 2.27M 1.16M 0.25M 0.07M
Ebit -30.67M -59.83M -71.83M -17.79M
Ebitda -28.41M -58.67M -71.58M -17.72M
Depreciation and amortization 2.27M 1.16M 0.25M 0.07M
Operating income -30.67M -59.83M -53.27M -18.27M
Other operating expenses 64.16M 64.76M 55.27M 18.27M
Interest expense - - 0.00M 0.20M
Tax provision 0.07M 0.05M - -
Interest income 2.54M 1.29M 0.00M 0.00M
Net interest income 2.54M 1.29M 0.00M -0.20M
Income tax expense 0.07M 0.05M -18.55M 0.68M
Total revenue 33.49M 4.93M 2.00M 0.00M
Total operating expenses 64.16M 64.76M 55.27M 18.27M
Total other income expense net 3.05M 1.49M -18.55M 0.28M
Net income from continuing ops -27.70M -58.39M -71.83M -17.99M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 105.11M 133.05M 169.93M 29.23M -
Other current assets 1.09M 1.62M 0.90M 0.67M -
Total liab 267.13M 273.75M 258.78M 50.80M -
Total stockholder equity -162.01M -140.70M -88.86M -21.57M -
Other current liab 8.02M 10.15M 10.13M 3.15M -
Capital stock 0.00M 0.00M 0.00M 0.00M -
Retained earnings -181.31M -152.59M -93.80M -21.98M -
Other assets - 0.01M - - -
Cash 53.50M 102.53M 160.92M 25.44M -
Total current liabilities 12.23M 25.62M 19.30M 5.76M -
Current deferred revenue - 10.89M 7.29M - -
Net debt -36.59M -83.08M -159.18M -23.33M 3.77M
Short term debt 3.60M 3.49M 0.43M 0.46M -
Short long term debt total 16.91M 19.45M 1.74M 2.12M -
Other stockholder equity 18.99M 11.89M 4.95M 0.41M -
Total current assets 79.82M 104.67M 162.29M 26.11M -
Short term investments 23.47M 0.00M - - -
Net receivables 1.76M 0.53M 0.47M 0.00M -
Long term debt - - - - 5.64M
Accounts payable 0.61M 1.10M 1.44M 2.15M -
Accumulated other comprehensive income 0.31M - - - -
Non currrent assets other 0.65M 0.76M 3.56M 0.73M -
Non current assets total 25.29M 28.37M 7.64M 3.13M -
Capital lease obligations 16.91M 19.45M 1.74M 2.12M -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments -25.98M -6.30M -1.72M -0.28M
Total cash from financing activities 24.39M -1.26M 152.75M 37.40M
Net income -28.72M -58.79M -71.83M -17.99M
Change in cash -49.01M -58.39M 135.73M 23.57M
Begin period cash flow 102.78M 161.17M 25.44M 1.87M
End period cash flow 53.76M 102.78M 161.17M 25.44M
Total cash from operating activities -47.43M -50.83M -15.30M -13.54M
Issuance of capital stock - - 154.61M 34.85M
Depreciation 2.27M 1.16M 0.25M 0.07M
Change to account receivables -0.51M -0.06M -0.47M 0.00M
Sale purchase of stock -0.01M -0.01M - -
Other cashflows from financing activities 24.40M -1.26M 152.75M 34.18M
Capital expenditures 3.26M 6.30M 1.72M 0.28M
Change in working capital -28.28M -3.87M 33.41M 4.36M
Stock based compensation 7.05M 6.58M 4.31M 0.30M
Other non cash items 0.25M - 18.55M -0.28M
Free cash flow -50.69M -57.13M -17.03M -13.82M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
ARTV
Artiva Biotherapeutics, Inc. Common Stock		 0.07
1.69%		 4.22 - - 109.91 1.43 59.57
NVO
Novo Nordisk A/S		 1.09
2.72%		 41.41 41.58 31.15 2.13 32.99 2.11
VRTX
Vertex Pharmaceuticals Inc		 3.78
0.69%		 550.87 30.22 24.27 10.36 6.50 9.99
REGN
Regeneron Pharmaceuticals Inc		 15.61
1.73%		 919.96 29.07 20.12 7.57 3.82 6.95
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38

Profile*

Artiva Biotherapeutics, Inc. Common Stock

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

5505 Morehouse Drive, San Diego, CA, United States, 92121

858 267 4467

https://www.artivabio.com

82

Name Title Year Born
Dr. Fred Aslan M.D. President, CEO & Director 1975
Dr. Peter Flynn Ph.D. Co-Founder & Strategic Advisor 1974
Ms. Jennifer Kinsbruner Bush Esq., J.D. Executive VP, COO, Chief Legal Officer, Corporate Secretary & Compliance Officer 1975
Mr. Christopher P. Horan Chief Technical Operations Officer 1967
Ms. Neha Krishnamohan CFO & Executive VP of Corporate Development 1987
Dr. Thorsten Graef M.D., Ph.D. Chief Medical Officer 1976
Dr. Heather Raymon Ph.D. Senior Vice President of Research & Early Development 1964
Mr. Javier Coindreau M.D. Senior VP of Medical Affairs NA
Dr. David Moriarty Ph.D. Senior VP of Clinical Operations NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.94
+37.96%
MOON
CAD 5.04
+14.17%
FDY
CAD 4.42
+12.18%
UCU
CAD 2.38
+11.21%
PDN
CAD 8.39
+11.13%
DIV
CAD 3.64
-10.57%
TOI
CAD 99.55
-4.99%
BSX
CAD 0.82
-4.65%
CSU
CAD 3367.07
-4.52%
LMN
CAD 26.82
-4.52%

Equity Sectors*

  • Basic Materials

    +5.01%

  • Communication Services

    -0.62%

  • Consumer Cyclical

    +1.25%

  • Consumer Defensive

    +0.14%

  • Energy

    +1.86%

  • Financial Services

    +1.87%

  • Healthcare

    +1.10%

  • Industrials

    +3.75%

  • Real Estate

    +0.53%

  • Technology

    +2.31%

  • Utilities

    +0.99%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…